Immunology/Inflammation

The adaptive immune system consists of B and T lymphocytes which mediate humoral immunity (e.g. antibody response) and cell-mediated immunity, respectively. B cell receptor and T cell receptor signaling is responsible for activation of Src family tyrosine kinases, such as Blk, Fyn, and Lyn in B cells and Fyn and Lck in T cells, resulting phosphorylation of the receptor-associated ITAM motifs. Phosphorylated ITAMs serve as the docking sites for Syk family tyrosine kinases, e.g. Syk in B cells and Zap-70 in T cells. Activated Syk kinases then propagate the signals via phosphorylation of downstream proteins. Furthermore, lymphocyte receptor signaling facilitates B and T cell development, differentiation, proliferation and survival.
-   A4217 QNZ (EVP4593)4 CitationSummary: Potent NF-κB inhibitor A4217 QNZ (EVP4593)4 CitationSummary: Potent NF-κB inhibitor
-   C4123 β-acetyl-Boswellic AcidSummary: non-reducing inhibitor of 5-lipoxygenase (5-LO) C4123 β-acetyl-Boswellic AcidSummary: non-reducing inhibitor of 5-lipoxygenase (5-LO)
-   B7085 CardamoninSummary: NF-κB inhibitor B7085 CardamoninSummary: NF-κB inhibitor
-   A4210 Bay 11-7821 (BAY 11-7082)1 CitationSummary: IKK/NF-κB/TNFα inhibitor A4210 Bay 11-7821 (BAY 11-7082)1 CitationSummary: IKK/NF-κB/TNFα inhibitor
-   B8014 ML355Summary: 12-LOX inhibitor B8014 ML355Summary: 12-LOX inhibitor
-   C4596 ATB-343Summary: hybrid molecule of an H2S donor and the NSAID indomethacin C4596 ATB-343Summary: hybrid molecule of an H2S donor and the NSAID indomethacin
-   B6853 Ro 106-9920Summary: Inhibitor of NF-κB activation B6853 Ro 106-9920Summary: Inhibitor of NF-κB activation
-   B7159 RWJ 21757Summary: Toll-like receptor 7 (TLR7) agonist B7159 RWJ 21757Summary: Toll-like receptor 7 (TLR7) agonist
-   A3635 MRT67307 HClTarget: TBK1|MARK1|NUAK1Summary: SIK/TBK-1/IKKe inhibitor A3635 MRT67307 HClTarget: TBK1|MARK1|NUAK1Summary: SIK/TBK-1/IKKe inhibitor
-   B5753 CU CPT 22Summary: toll-like receptor 1/2 (TLR1/2) inhibitor B5753 CU CPT 22Summary: toll-like receptor 1/2 (TLR1/2) inhibitor
